4
Changes in Ownership
Intellia Therapeutics, Inc. Filed Acc 0001209191-22-015960
EVP, Chief Medical Officer sold 1,051 shares at $112.24 ($117,964)
- EVP, Chief Medical Officer acquired 13,816 shares (grant or award)
- EVP, Chief Medical Officer acquired 3,187 shares (option exercise)
From the SEC's structured data for this filing
Trades in this filing
Table I: Non-derivative
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Lebwohl David EVP, Chief Medical Officer | 2022-01-01 | Option exercise | +3,187 | 11,973 | D: show line 1 in the form | ||
| Lebwohl David EVP, Chief Medical Officer | 2022-01-01 | Sale | −1,051 | $112.24 | $117,964 | 10,922 | D: show line 2 in the form |
| Lebwohl David EVP, Chief Medical Officer | 2022-03-01 | Grant or award | +13,816 | 24,738 | D: show line 3 in the form | ||
| Open-market sales · 1,051 sh · avg $112.24 · $117,964 | |||||||
Table II: Derivative
| Insider | Date | Transaction | Shares | Price | Value | Exercise | Expires | Underlying | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|
| Lebwohl David EVP, Chief Medical Officer | 2022-01-01 | Option exercise · Restricted Stock Unit | −3,187 | 9,563 | D: show line 4 in the form | |||||
| Lebwohl David EVP, Chief Medical Officer | 2022-03-01 | Grant or award · Stock Option (right to buy) | +13,816 | 13,816 | D: show line 5 in the form |
Loading xslF345X03/doc4.xml…